Cargando…

Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model

BACKGROUND: Anticholinergic burden has been associated with adverse outcomes such as falls. To date, no gold standard measure has been identified to assess anticholinergic burden, and no conclusion has been drawn on which of the different measure algorithms best predicts falls in older patients from...

Descripción completa

Detalles Bibliográficos
Autores principales: Dinh, Truc Sophia, Meid, Andreas D., Rudolf, Henrik, Brueckle, Maria-Sophie, González-González, Ana I., Bencheva, Veronika, Gogolin, Matthias, Snell, Kym I. E., Elders, Petra J. M., Thuermann, Petra A., Donner-Banzhoff, Norbert, Blom, Jeanet W., van den Akker, Marjan, Gerlach, Ferdinand M., Harder, Sebastian, Thiem, Ulrich, Glasziou, Paul P., Haefeli, Walter E., Muth, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870119/
https://www.ncbi.nlm.nih.gov/pubmed/36689445
http://dx.doi.org/10.1371/journal.pone.0280907
_version_ 1784876905281880064
author Dinh, Truc Sophia
Meid, Andreas D.
Rudolf, Henrik
Brueckle, Maria-Sophie
González-González, Ana I.
Bencheva, Veronika
Gogolin, Matthias
Snell, Kym I. E.
Elders, Petra J. M.
Thuermann, Petra A.
Donner-Banzhoff, Norbert
Blom, Jeanet W.
van den Akker, Marjan
Gerlach, Ferdinand M.
Harder, Sebastian
Thiem, Ulrich
Glasziou, Paul P.
Haefeli, Walter E.
Muth, Christiane
author_facet Dinh, Truc Sophia
Meid, Andreas D.
Rudolf, Henrik
Brueckle, Maria-Sophie
González-González, Ana I.
Bencheva, Veronika
Gogolin, Matthias
Snell, Kym I. E.
Elders, Petra J. M.
Thuermann, Petra A.
Donner-Banzhoff, Norbert
Blom, Jeanet W.
van den Akker, Marjan
Gerlach, Ferdinand M.
Harder, Sebastian
Thiem, Ulrich
Glasziou, Paul P.
Haefeli, Walter E.
Muth, Christiane
author_sort Dinh, Truc Sophia
collection PubMed
description BACKGROUND: Anticholinergic burden has been associated with adverse outcomes such as falls. To date, no gold standard measure has been identified to assess anticholinergic burden, and no conclusion has been drawn on which of the different measure algorithms best predicts falls in older patients from general practice. This study compared the ability of five measures of anticholinergic burden to predict falls. To account for patients’ individual susceptibility to medications, the added predictive value of typical anticholinergic symptoms was further quantified in this context. METHODS AND FINDINGS: To predict falls, models were developed and validated based on logistic regression models created using data from two German cluster-randomized controlled trials. The outcome was defined as “≥ 1 fall” vs. “no fall” within a 6-month follow-up period. Data from the RIME study (n = 1,197) were used in model development, and from PRIMUM (n = 502) for external validation. The models were developed step-wise in order to quantify the predictive ability of anticholinergic burden measures, and anticholinergic symptoms. In the development set, 1,015 patients had complete data and 188 (18.5%) experienced ≥ 1 fall within the 6-month follow-up period. The overall predictive value of the five anticholinergic measures was limited, with neither the employed anticholinergic variable (binary / count / burden), nor dose-dependent or dose-independent measures differing significantly in their ability to predict falls. The highest c-statistic was obtained using the German Anticholinergic Burden Score (0.73), whereby the optimism-corrected c-statistic was 0.71 after interval validation using bootstrapping and 0.63 in the external validation. Previous falls and dizziness / vertigo had the strongest prognostic value in all models. CONCLUSIONS: The ability of anticholinergic burden measures to predict falls does not appear to differ significantly, and the added value they contribute to risk classification in fall-prediction models is limited. Previous falls and dizziness / vertigo contributed most to model performance.
format Online
Article
Text
id pubmed-9870119
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-98701192023-01-24 Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model Dinh, Truc Sophia Meid, Andreas D. Rudolf, Henrik Brueckle, Maria-Sophie González-González, Ana I. Bencheva, Veronika Gogolin, Matthias Snell, Kym I. E. Elders, Petra J. M. Thuermann, Petra A. Donner-Banzhoff, Norbert Blom, Jeanet W. van den Akker, Marjan Gerlach, Ferdinand M. Harder, Sebastian Thiem, Ulrich Glasziou, Paul P. Haefeli, Walter E. Muth, Christiane PLoS One Research Article BACKGROUND: Anticholinergic burden has been associated with adverse outcomes such as falls. To date, no gold standard measure has been identified to assess anticholinergic burden, and no conclusion has been drawn on which of the different measure algorithms best predicts falls in older patients from general practice. This study compared the ability of five measures of anticholinergic burden to predict falls. To account for patients’ individual susceptibility to medications, the added predictive value of typical anticholinergic symptoms was further quantified in this context. METHODS AND FINDINGS: To predict falls, models were developed and validated based on logistic regression models created using data from two German cluster-randomized controlled trials. The outcome was defined as “≥ 1 fall” vs. “no fall” within a 6-month follow-up period. Data from the RIME study (n = 1,197) were used in model development, and from PRIMUM (n = 502) for external validation. The models were developed step-wise in order to quantify the predictive ability of anticholinergic burden measures, and anticholinergic symptoms. In the development set, 1,015 patients had complete data and 188 (18.5%) experienced ≥ 1 fall within the 6-month follow-up period. The overall predictive value of the five anticholinergic measures was limited, with neither the employed anticholinergic variable (binary / count / burden), nor dose-dependent or dose-independent measures differing significantly in their ability to predict falls. The highest c-statistic was obtained using the German Anticholinergic Burden Score (0.73), whereby the optimism-corrected c-statistic was 0.71 after interval validation using bootstrapping and 0.63 in the external validation. Previous falls and dizziness / vertigo had the strongest prognostic value in all models. CONCLUSIONS: The ability of anticholinergic burden measures to predict falls does not appear to differ significantly, and the added value they contribute to risk classification in fall-prediction models is limited. Previous falls and dizziness / vertigo contributed most to model performance. Public Library of Science 2023-01-23 /pmc/articles/PMC9870119/ /pubmed/36689445 http://dx.doi.org/10.1371/journal.pone.0280907 Text en © 2023 Dinh et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Dinh, Truc Sophia
Meid, Andreas D.
Rudolf, Henrik
Brueckle, Maria-Sophie
González-González, Ana I.
Bencheva, Veronika
Gogolin, Matthias
Snell, Kym I. E.
Elders, Petra J. M.
Thuermann, Petra A.
Donner-Banzhoff, Norbert
Blom, Jeanet W.
van den Akker, Marjan
Gerlach, Ferdinand M.
Harder, Sebastian
Thiem, Ulrich
Glasziou, Paul P.
Haefeli, Walter E.
Muth, Christiane
Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model
title Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model
title_full Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model
title_fullStr Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model
title_full_unstemmed Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model
title_short Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model
title_sort anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: development and validation of a prognostic model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870119/
https://www.ncbi.nlm.nih.gov/pubmed/36689445
http://dx.doi.org/10.1371/journal.pone.0280907
work_keys_str_mv AT dinhtrucsophia anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT meidandreasd anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT rudolfhenrik anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT bruecklemariasophie anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT gonzalezgonzalezanai anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT benchevaveronika anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT gogolinmatthias anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT snellkymie anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT elderspetrajm anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT thuermannpetraa anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT donnerbanzhoffnorbert anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT blomjeanetw anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT vandenakkermarjan anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT gerlachferdinandm anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT hardersebastian anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT thiemulrich anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT glaszioupaulp anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT haefeliwaltere anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel
AT muthchristiane anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel